SamanTree Medical, a European innovator in surgical imaging technology, has secured €20 million in funding from the European Investment Bank through its Venture Debt Instrument. The operation is supported by InvestEU, the European Union’s flagship program designed to mobilize over €372 billion in additional investment from 2021 to 2027. Olivier Delporte, CEO of SamanTree Medical, said that the rigorous evaluation process reflects the significance of the company’s technology, its development strategy, and its long-term vision to advance real-time, high-resolution imaging of excised tissue during surgeries.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
The financing will accelerate the development of SamanTree’s Histolog Scanner, an advanced confocal microscopy system capable of rapid imaging of tissue microstructures. The investment will also support research, development, and innovation initiatives aimed at improving surgical outcomes and expanding commercial reach across Europe and the United States. Delporte emphasized that this funding allows the company to advance both its technology and its global presence while maintaining its focus on precision and innovation in surgical care.
Health Technology Insights: Adagio Medical Adds Executives to Boost ULTC Launch
Alessandro Izzo, Director at the EIB, highlighted that the bank’s support demonstrates its commitment to fostering medical innovation across Europe. He stated that venture debt enables medical technology companies like SamanTree to accelerate growth and bring life-saving innovations to patients more quickly, reinforcing the bank’s mission to drive positive impact for healthcare systems and patient care.
The Histolog Scanner captures nearly 30,000 images simultaneously, generating high-resolution, histology-like images in about one minute without damaging the tissue. This enables surgeons and pathologists to assess tissue immediately during operations, reducing the risk of residual abnormal cells. The scanner has been used in over 6,000 patients, showing compelling results across various tissue types. In breast-conserving surgeries, the SHIELD study demonstrated that using Histolog images lowered reoperation rates from 30% to 10%, a 67% reduction.
Studies comparing the Histolog Scanner to traditional intraoperative frozen-section analysis for prostatectomies show similar accuracy while significantly reducing procedure time. Imaging and interpretation using Histolog takes five to twenty minutes compared with forty-five to sixty minutes for conventional frozen-section analysis. Research also shows that intraoperative use of the scanner allows surgeons to perform more nerve-sparing procedures, substantially reducing side effects such as erectile dysfunction following radical prostatectomy.
This funding positions SamanTree Medical to continue transforming surgical pathology, improving efficiency, outcomes, and precision for patients worldwide while expanding its innovative technologies to new markets.
Health Technology Insights: ACCO Brands to Acquire EPOS
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
